Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant

Summary

TAF treatment for HBV prophylaxis could lead to significant reduction in ALT and significant improvement in renal function. However, data are scarce regarding to TAF monotherapy without HBIG for HBV prophylaxis in post orthotopic liver transplant with HBV-related disease. This study is based on a real-world, multi-center, prospective study to assess the effectiveness and safety of TAF for HBV prophylaxis, which will fill in gaps with TAF monotherapy without HBIG in post liver transplant.

Timeline

Start

2021-07-29

Primary completion

2022-07-29

Completion

2022-12-29

Drugs

Indications